RVTY logo

REVVITY INC

RVTYNYSE
๐Ÿ† #634 by market capEarnings Oct 26US Equity
$152.77โ–ฒ $1.77 (+1.16%)
๐ŸŒ™ After hours$152.69โ–ผ 0.05%Regular close ยท extended-hours price shown
๐Ÿ””
Track RVTY
Get earnings, price moves & breaking news on Telegram
Track
24hโ–ฒ 1.2%
7dโ–ฒ 6.6%
14dโ–ฒ 9.0%
30dโ–ฒ 18.6%
ytdโ–ฒ 57.8%
1yโ–ฒ 81.2%
๐ŸฆMarket Cap
$17.04B
Mid Cap
๐Ÿ“ˆRevenue Growth (YoY)
+4.0%
Slowing
๐Ÿ“ŠGross Margin
55.0%
Healthy
๐Ÿ’ตFCF Margin
19.2%
Healthy
โš–๏ธP/S Ratio
5.7x
Fair
Otter Score
76
Good

Trading Snapshot

Day Range
$151.06 โ€“ $153.99
52-Week Range
$81.22 โ€“ $152.26
Volume
$1.71B
Avg Volume
$1.72B
Shares Outstanding
111.6M
Next Earnings
Nov 30, 2026

Fundamentals Snapshot

Annual Revenue
$2.86B
Last Q Revenue
$730M
P/E Ratio
70.3
P/S Ratio
5.7x
EPS (TTM)
$2.10
Dividend Yield
0.19%
Dilution (1yr)
โˆ’6.9%

Why Investors Own RVTY

  • โœ“High-growth profile โ€” revenue up +8.9% YoY with expanding US Equity exposure.
  • โœ“Healthy economics โ€” 49% gross margin and 18% free-cash-flow margin.
  • โœ“New products and segments could unlock additional revenue streams.
โš ๏ธ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

RVTY logo

REVVITY INC

RVTY
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$2.9Bโ–ฒ +3.7% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
53.1%โ–ฒ +10.6% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isnโ€™t profitable yet.
$357Mโ–ผ โˆ’13.1% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$508Mโ–ผ โˆ’6.2% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing ownerโ€™s slice.
113.2Mโ–ผ โˆ’6.9% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
โˆ’$2.6Bโ–ผ โˆ’$434M YoY
StockOtter ยท stockotter.space

About REVVITY INC

Revvity, Inc., founded in 1937 and based in Waltham, Massachusetts, is a global enterprise that develops and delivers a wide array of products, services, and solutions. The company, which changed its name from PerkinElmer, Inc. in April 2023, caters to the diagnostics, life sciences, and applied services sectors worldwide. Its Discovery & Analytical Solutions division provides advanced instrumentation, reagents, informatics, software, subscriptions, and sophisticated detection and imaging technologies. These resources are designed to enable scientists to achieve significant breakthroughs in life sciences research. This segment also offers contract research and specialized laboratory services. Furthermore, it supplies analytical tools and services for assessing environmental health, including air, water, and soil, and delivers solutions to agricultural and food producers. It also serves the industrial market with analytical instrumentation for sectors such as chemical, semiconductor, electronics, energy, lubricants, petrochemicals, and polymers. The Diagnostics segment is dedicated to early detection, offering instruments, reagents, assay platforms, and software for identifying genetic disorders in pregnant individuals and young children, alongside infectious disease testing. Its products facilitate the screening of genetic abnormalities, disorders, and diseases like Down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This division also innovates technologies that support genomic workflows, leveraging protein-coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. Revvity serves a diverse clientele, including pharmaceutical and biotechnology firms, laboratories, academic and research institutions, public health authorities, private healthcare organizations, medical professionals, and government bodies.

๐Ÿฆฆ

Otter Score Breakdown

How it's scoredFive components, each rated 1โ€“5โ˜… and equally weighted (20%), averaged to a 0โ€“100 score:๐Ÿ’Ž Quality โ€” gross margin๐Ÿš€ Growth โ€” revenue YoYโš–๏ธ Valuation โ€” P/S ratioโšก Momentum โ€” 30-day price change๐Ÿ’ง Dilution โ€” 1-yr share issuance (buybacks score higher)
๐Ÿ’ŽQualityโ˜…โ˜…โ˜…โ˜…โ˜…
๐Ÿš€Growthโ˜…โ˜…โ˜…โ˜…โ˜…
โš–๏ธValuationโ˜…โ˜…โ˜…โ˜…โ˜…
โšกMomentumโ˜…โ˜…โ˜…โ˜…โ˜…
๐Ÿ’งDilutionโ˜…โ˜…โ˜…โ˜…โ˜…
Overall Score
Good
76/100

Analyst Price Target

โ“˜
Average Target
$164.54
โ–ฒ +7.7% Upside
High Target$181.27
Low Target$130.01
Based on 36 analysts

Latest News & Updates

๐Ÿš€
Zacks Investment Researchยท10h ago

Here's Why You Should Retain Revvity Stock in Your Portfolio for Now

RVTY's diagnostics growth, AI-driven demand and life sciences expansion support its outlook, though China and margin pressures pose near-term challenges.

Zacks Investment Researchยท4d ago

RVTY Launches New Kit in Europe for Newborn Type 1 Diabetes Detection

Revvity launches a CE-IVDR-certified automated T1D screening kit for children, expanding its GSP platform from newborn screening into early childhood.

Business Wireยท5d ago

Revvity Launches IVDR-Certified Solution for Early Detection of Type 1 Diabetes

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) today announced the launch of the GSPยฎ T1D 3plex kit, a fully automated, CE-IVDR-certified, multiplex autoantibody (AAb) detection solution to enable population

Defense Worldยท5d ago

Reviewing Codexis (NASDAQ:CDXS) & Revvity (NYSE:RVTY)

Revvity (NYSE: RVTY - Get Free Report) and Codexis (NASDAQ: CDXS - Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuat

Defense Worldยท5d ago

Revvity Inc. $RVTY Shares Acquired by State Street Corp

State Street Corp boosted its stake in Revvity Inc. (NYSE: RVTY) by 0.8% during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 4,342,739 shares

Defense Worldยท11d ago

Critical Survey: Revvity (NYSE:RVTY) vs. Cytek Biosciences (NASDAQ:CTKB)

Revvity (NYSE: RVTY - Get Free Report) and Cytek Biosciences (NASDAQ: CTKB - Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of